[摘 要] 目的 观察降纤酶、低分子肝素(速避凝)联合应用治疗不稳定型心绞痛(UAP)的临床疗效及安全性。方法 60例 UAP病人随机分成治疗组和对照组，治疗组在对照组严格内科药物治疗基础上，用降纤酶10 U、5 U、5 U加入0.9%氯化纳注射液250 ml分别于入院第1、3、5 d静滴，滴注时间为1~1.5 h。观察两组心绞痛发作及心电图变化，1周后评定疗效。结果 治疗组显效率50%，总有效率93%，对照组显效率27%，总有效率77%；两组比较显效及总有效率有统计学显著差异(P<0.05)。结论 在设备技术相对薄弱的基层医院，对于经严格内科药物治疗无效的心绞痛，降纤酶与低分子肝素联合应用不失为有益的可供选择的治疗方法，使用简便安全，不良反应少。

    [关键词] 降纤酶；低分子肝素；心绞痛

    Treatment of unstable angina pectoris with combination of defibrase and low molecular weight heparin calcium

    LUO Liu-su, LI Qiang, LIAO Wei-chun, LI Hai-yan

    (People's Hospital of Xingning County, Xingning 514500, Guangdong Province, China)

    Abstract: Objective To investigate the therapeutic efficacy and safety of combined application of defibrase and low molecular weight heparin calcium (Fraxiparine) in unstable angina pectoris (UAP). Methods A total of 60 cases of UAP were randomly assigned into treatment and control groups. Patients in treatment group were administered intravenously with defibrase at the doses of 10 u, 5 u, and 5 u dissolved in 250 ml of 0.9% NaCl solution for 1 - 1.5 h on the first, third, and fifth day after admission to hospital besides strict routine medication. Attacks of angina and changes of electrocardiogram were observed. Clinical outcomes were evaluated one week later. Results Significant effective rate and total effective rate in the treatment group were 50% and 93%, while those in the control group were 27% and 77%, respectively. There was significant difference in significant effective rate and total effective rate between the two groups (P<0.05). Conclusion Combined application of defibrase and low molecular weight heparin is a convenient and safe method with little side effects for the treatment of refractory UAP by routine therapy in patients admitted to poorly equipped hospitals. ......